Another alternative to this is that the 5-HT4 agonist currently available for use in humans do not have great enough potency or bioavailability in the brain to elicit the same effects.
Another option is that the 5-HT4 agonist currently available for use in humans lacks sufficient potency or bioavailability within the brain to produce the same effects.